Business Wire

CO-OPTIV-SECURITY

Share
Businesses are Prioritising Cybersecurity Above All Else, Optiv Security Report Finds

With the rise of the data breach epidemic, and the imposition of comprehensive privacy regulations and significant legislation requirements, cybersecurity has become a tier-one business risk. As a result, the chief information security officer’s (CISO) role in a business has dramatically increased in value. In fact, 64 percent of businesses now prioritise cybersecurity above all else, even if it slows some users’ productivity down, according to a new research report from Optiv Security . The report, “The State of the CISO,” takes an in-depth look at the approach to cybersecurity taken by CISOs, CSOs and senior IT decision makers, the strategies they have in place and their experience of data breaches.

Cybersecurity becomes a business priority

The research found that the importance of cybersecurity is now better understood by business executives and board members. In fact, 96 percent of respondents indicated they are taking a more strategic approach to cybersecurity as a result of being greater aligned with business leaders.

“Some organisations are further along this evolutionary curve than others, but without business’ buy-in to a cybersecurity program, CISOs will undoubtedly struggle to keep their organisations safe from looming cyber threats,” said Andrzej Kawalec, Optiv’s director of strategy and technology, Europe. “We are seeing a significant shift in the industry, whereby cybersecurity is now a business issue. CISOs are being regarded as an important part of major business initiatives such as next-generation digital transformation, which has led to more funding for cyber programs. The board now understands that a major security or compliance miscue can derail a business.”

When it comes to the approach to cybersecurity, the research found that 66 percent of IT security decision makers felt greater awareness of security risks within the IT function has had a significant impact on currently existing cybersecurity policies. Compliance with external standards such as GDPR follows closely behind at 56 percent, but basic functions like vulnerability and patching is only prioritised by 32 percent of respondents. Employee education was deemed a top priority by 58 percent of respondents, as was simplifying infrastructure (54 percent) and aligning security with development operations to create a DevSecOps model (47 percent).

“It is concerning in light of the fact that, by some estimates, unpatched vulnerabilities account for more than half of all data breaches,” continued Kawalec. “By getting the basic functions of cybersecurity right, IT decision makers can drastically improve their chances of defending against a cyber-attack, since unpatched software is often cited as the most common cause of data breaches.”

The greatest security threats

The research also identified that 31 percent of respondents believe that organized crime and politically motivated acts are seen as the greatest threats to cybersecurity, while 28 percent believe this to be hacktivists. Insider threats are seen as critical by 26 percent and just 15 percent of respondents cited third parties as a threat to their cybersecurity. To deal with cybersecurity threats, 92 percent of respondents have an incident response plan in place, but rehearsing this plan is lagging, with 44 percent of businesses stating they only rehearse once a year or less.

The report finds that breaches still seem to serve as a wake-up call for organizations, with 39 percent of businesses implementing changes in their security program only after an incident. While 65 percent cited that recovery from the breach was well coordinated and successful, over a third (35 percent) reported that recovery costs were still higher than it would have cost to invest in better breach defence.

To read the full report, please visit Optiv’s website .

Methodology

Optiv launched an independent research series to discover how IT decision makers approach cybersecurity. To produce its research and resulting report, Optiv worked with London-based research agency, Loudhouse. Loudhouse is an independent agency that specializes in technology and B2B research for global brands.

Loudhouse conducted online interviews with 100 US- and 100 UK-based CISOs, CSOs and Senior IT decision makers at enterprise businesses (between 500 and 5000+ employees), to understand their approach to cybersecurity, the strategies they have in place, and their experience of data breaches.

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: https://www.optiv.com/explore-optiv-insights/blog

Optiv Security: Who Secures Your Insecurity?
Optiv is a security solutions integrator – a global, “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organisations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye